Role of Immune Responses After Acute Myocardial Infarction

Status Recruiting

Clinical Trial Summary

The fascinating role of lymphocyte subtypes in the development of coronary artery disease may be a new strategic target for understanding and therapy of acute myocardial infarction. The determinants of cell viability are unknown, postulating that they arise from factors not only related to microcirculation or energy expenditure, but also to inflammatory and immune responses. Furthermore, the intense mobilization of progenitor cells secondary to myocardial infarction triggers large lymphocyte proliferation that colonizes plaques in development, contributing to recurrent ischemic outcomes. This project aims to evaluate the immune and metabolic mechanisms involved in the recovery of the ischemic myocardium and coronary disease progression.

Clinical Trial Description

Specifically, the investigators will study the innate and adaptive immunity, with emphasis on lymphocytes subtypes involved in the early and late surrogate outcomes of patients with acute myocardial infarction, their characterization (B1, B2 and T lymphocytes) in cell culture and by flow-cytometry, and immune responses (IgM and IgG for oxLDL and specific epitopes of apoB). In addition, the project will evaluate new biomarkers identified by studies of metabolomics, as well as the corresponding signaling pathways. Therapeutic pharmacological strategies and changes on intestinal microbiota will be evaluated since the acute phase of myocardial infarction up to 6 months.

In the study, the investigators will compared four arms of combined therapy: clopidogrel with rosuvastatin; or clopidogrel with simvastatin; or ticagrelor with rosuvastatin; or ticagrelor with simvastatin. The investigator's hypothesis is that the improvement of microcirculation with rosuvastatin and ticagrelor (synergic pleiotropic effects) may decrease the infarcted mass area, resulting in better left ventricular ejection fraction when compared to the other combined therapies.

The monitoring and genotype of microbiota will be examined together the metabolomics and cardiac MRIs obtained at the acute phase of MI and after 1-mo and 6-mo FU. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02428374
Study type	Interventional
Source	Federal University of São Paulo
Contact	Francisco A Fonseca, MD, PhD
Phone	+55 11 992639082
Email	fahfonseca@terra.com.br
Status	Recruiting
Phase	Phase 4
Start date	May 2015
Completion date	July 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03332745` - Mechanism of Decompensation Evaluation - Aortic Stenosis
Not yet recruiting	`NCT05954559` - High Relaxivity Contrast Agent for Cardiac MR in the Myocardial Scar Assessment	Phase 4
Recruiting	`NCT03176862` - Left Ventricular Fibrosis in Chronic Kidney Disease	N/A
Recruiting	`NCT06039969` - Evaluate Aerobic Exercise on Myocardial Fibrosis and Intestinal Flora in Dilated Cardiomyopathy Diagnosed First Time.
Not yet recruiting	`NCT06059287` - The Effect of Henagliflozin and Metformin on Myocardial Tissue-level Characteristics	N/A
Completed	`NCT00879060` - Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy	Phase 4
Completed	`NCT02834104` - Validation of Fibrosis Quantification Using T1 Mapping Against Histology as Reference and Comparison With Fibrosis Biomarkers	N/A
Active, not recruiting	`NCT04444128` - IMPRoving Cardiovascular RiSk Stratification Using T1 Mapping in General populatION
Recruiting	`NCT03191461` - Myocardial Perfusion and Fibrosis in Cancer Survivors
Recruiting	`NCT05867589` - Study of Novel PET Tracer Gallium [68Ga]/ Fluorine [18F] -FAPI-04 in the Diagnosis of Cardiovascular Diseases	N/A
Not yet recruiting	`NCT06326970` - SPECT Fibroblast Activation Protein Imaging in Patients With Cardiac Disease
Completed	`NCT02432885` - Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy - ACE Inhibitor Therapy Trial	Phase 3
Completed	`NCT04397198` - The Assessment Of Myocardial Viability Based On CTA/MRI Hybrid Models
Recruiting	`NCT03405987` - Association of T1-mapping and LV Strain Analysis by CMR
Completed	`NCT01160471` - Noninvasive Imaging of Heart Failure: A Pilot Study
Completed	`NCT03422770` - Ultrasonic Markers for Myocardial Fibrosis and Prognosis in Aortic Stenosis	N/A
Not yet recruiting	`NCT03515291` - A Trial of Cardiac Injections of iMP Cells During CABG Surgery	Phase 2
Recruiting	`NCT02670031` - Response of the Myocardium to Hypertrophic Conditions in the Adult Population
Terminated	`NCT02012725` - Molecular MRI of the Fibrotic Heart	N/A
Completed	`NCT02727725` - An Evaluation Of The Novel TRAMINER Sequence By Comparison To Late Gadolinium Enhancement Images	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Role of Immune Responses After Acute Myocardial Infarction — BATTLE-AMI

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms